Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/12670564

Download in:

View as

General Info

Authors

Ni YX, Wood D, Smith DC, Hussain M, Vaishampayan U, Sakr W, Fontana J, El-Rayes BF

Affiliation

Division of Hematology/Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.

Abstract

To evaluate the efficacy and safety of neoadjuvant docetaxel and estramustine in patients with high-risk, newly diagnosed, prostate cancer.

PMID
12670564

Publication types

Clinical Trial; Comparative Study; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't; Clinical Trial, Phase II